REGN
Regeneron Pharmaceuticals, Inc.
REGN's fundamentals are strong: revenue grew 19% and it turned 23% of its revenue into free cash flow. At 21x earnings, it's trading above its usual 18x. Analysts expect that strong growth to continue, though they disagree widely on how much.
REGN Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Healthy | |
| Strong |
REGN's revenue, profitability, cash flow and balance sheet are all currently healthy.
REGN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $951 | — |
| Cheap | 13x | $589 | -38% |
| Fair | 18x | $822 | -14% |
| Current | 21x | $951 | — |
| Expensive | 25x | $1,135 | +19% |
Historical ranges are pointers, not guarantees.
REGN's PE is in its expensive range at 21x. If earnings grow as analysts expect, today's price would be 12x next year's earnings, in its cheap range.
REGN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for REGN, with profitability improving. However, they disagree widely on these estimates.
REGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $79.95 | +77% |
| Q3 2026 | $45.21 | +8.1% |
| Q2 2026 | $40.38 | +1.6% |
| Q1 2026 | $40.96 | +4.1% |
| Q4 2025 | $41.48 | +8.2% |
| Q3 2025 | $41.82 | +3.4% |
| Q2 2025 | $39.74 | +5.2% |
| Q1 2025 | $39.34 | +16% |
| Q4 2024 | $38.34 | +10% |
REGN's earnings per share have fallen from their peak: $45.21 over the past year, against $71.97 in late 2021.
REGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +36% |
| Q2 2026 | $4.3B | +17% |
| Q1 2026 | $3.6B | +19% |
| Q4 2025 | $3.9B | +2.5% |
| Q3 2025 | $3.8B | +0.9% |
| Q2 2025 | $3.7B | +3.6% |
| Q1 2025 | $3B | -3.7% |
| Q4 2024 | $3.8B | +10% |
REGN's revenue has grown year over year for six quarters in a row: $5.1B last quarter, up 36% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | +13 points |
| Q2 2026 | 30% | +0.8 points |
| Q1 2026 | 18% | -1.7 points |
| Q4 2025 | 23% | -3.5 points |
| Q3 2025 | 27% | -4.3 points |
| Q2 2025 | 29% | -0.8 points |
| Q1 2025 | 20% | -4.4 points |
| Q4 2024 | 26% | -2.2 points |
REGN's operating margin was 40% last quarter, up 13 points from the same quarter a year ago.
REGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +4.6% |
| Q2 2026 | $572.8M | -38% |
| Q1 2026 | $848.3M | +4% |
| Q4 2025 | $922M | -13% |
| Q3 2025 | $1.4B | +35% |
| Q2 2025 | $925.4M | +433% |
| Q1 2025 | $815.8M | -41% |
| Q4 2024 | $1.1B | +27% |
REGN still generates free cash flow, though less than at its 2021 peak: $3.8B over the past year.
REGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -400K shares |
| 1 year | -1.5% | -1.6M shares |
| 3 years | -6.9% | -7.8M shares |
| 5 years | -7.3% | -8.3M shares |
| Available history | -7.9% | -9M shares |
REGN has 106M diluted shares, down 1.5% from a year ago, with $3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $399.7M |
| Q2 2026 | $1.2B |
| Q1 2026 | $794.3M |
| Q4 2025 | $671.7M |
| Q3 2025 | $664M |
| Q2 2025 | $1.1B |
| Q1 2025 | $1B |
| Q4 2024 | $973M |
REGN spent $3B buying back its own shares over the past year, down 19% from the year before.
REGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.1x | Net Cash |
| Q1 2026 | -0.2x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Very low |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | -0.1x | Net Cash |
REGN has more cash than debt.
REGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.3 | Neutral |
| Stochastic | 83.3 | Overbought |
REGN's weekly RSI is 69 (neutral) and its Stochastic is 83 (overbought).
REGN PE vs Healthcare Sector
| Metric | REGN | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 19% below |
| PE % | 70 | 29 | 41 pts above |
REGN is trading at 21x earnings, a 19% discount to the Healthcare sector's median of 26x.
REGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $831.1 | 14% above |
| 20 week MA | $783.7 | 21% above |
| 50 week MA | $749.7 | 27% above |
| 100 week MA | $681.9 | 39% above |
| 200 week MA | $782.7 | 22% above |
REGN has climbed back above all five of its weekly moving averages, and it's now 22% above its 200-week average.
REGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $373.3 | $488.9 | +31% |
| 2021 | $488.9 | $625.4 | +28% |
| 2022 | $625.4 | $726.7 | +16% |
| 2023 | $726.7 | $878.3 | +21% |
| 2024 | $878.3 | $712.4 | -19% |
| 2025 | $712.4 | $785.0 | +10% |
| 2026 YTD | $785.0 | $951.2 | +21% |
REGN has finished higher in five of the last six years. It's up 21% so far in 2026.